[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"LeMaitre Vascular, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":72},{"warningLetters":4,"total":71},[5,31,50],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},693,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-11T04:00:00Z\">08\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flemaitre-vascular-inc-713502-08112025\">LeMaitre Vascular, Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. George LeMaitre\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>LeMaitre Vascular, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>63 Second Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Burlington\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:glemaitre@lemaitre.com\"> glemaitre@lemaitre.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 713502\u003C\u002Fp>\u003Cp>August 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. LeMaitre:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in North Brunswick, NJ from March 4, 2025, through April 16, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures Artegraft Collagen Vascular Grafts. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from Monte Nelson, Sr. Director, Quality Affairs - Artegraft dated May 7, 2025, and August 5, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the May 7, 2025, response below, in relation to each of the noted violations. Any additional responses will be reviewed as part of your response to this letter.\u003C\u002Fp>\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(e). Specifically,\u003C\u002Fp>\u003Cp>a. USP water sampling procedures utilized by your firm for testing of conductivity, Total Organic Carbon (TOC), endotoxin, and microbial contamination contain inconsistent and conflicting requirements that ensure water being sampled is representative of water used in production of the Artegraft Collagen Vascular Graft devices. Specifically,\u003C\u002Fp>\u003Cp>i. Water samples for monitoring are being taken through a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and not \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the Point of Use (POU) as required by SOP 103, Sampling of the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Systems, section 6.5 states that \u003Cstrong>(b)(4) \u003C\u002Fstrong>samples be tested from points of use (POU) according to FRM 103-03.\u003C\u002Fp>\u003Cp>ii. SOP 103 is not adequate since it requires the water to be purged after system sanitization for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling (section 6.12.1), requires the system to be flushed for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling (section 6.12.2), and requires the sample port to be sprayed with \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling (section 6.12.5). The purging, cleaning, and spraying the sample port with \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling are not representative of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> use of the water system used during production.\u003C\u002Fp>\u003Cp>iii. WI MFG-040, Operation of the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system Equipment ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong> is not adequate since it states sample valves (SVs) will be cleaned when sampling is performed in accordance with SOP 103 (section 6.8.11.2) and states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> POUs (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-POU) only will be cleaned when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is necessary, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> system sanitation has been performed (section 6.8.11.3). This cleaning and sanitation \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling are not representative of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> use of the water system used during production.\u003C\u002Fp>\u003Cp>b. Your firm changed the sterilant solution used for sanitization of the USP \u003Cstrong>(b)(4) \u003C\u002Fstrong>Water Systems utilized in the manufacturing process. Your firm utilizes procedure MP-059, Preventive Maintenance of the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Systems which in sections 6.4.2 and 6.4.3 specify that \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution is used. However, the Maintenance Log Sheet for the USP Water System Monitoring (FRM MP-06; dated 11\u002F27\u002F24) states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used for system sanitization. During the inspection, your firm’s Sr. Quality Engineer stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was discontinued sometime in 2024. Your firm was unable to provide any documentation during the inspection that allowed for a different sterilant solution to be used per procedure MP-059, nor that your firm has assessed the impact of the new sterilant on devices manufactured by your firm such as on the biocompatibility or if the new sterilant has different ingredients (e.g., potential contaminants).\u003C\u002Fp>\u003Cp>c. Your firm is not documenting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> replacement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> during water sampling (section 6.5.2) which is required per SOP 103, Sampling of the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Systems, which states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is to be replaced by a member of the quality team during \u003Cstrong>(b)(4)\u003C\u002Fstrong> water sampling as per SOP 102 – Workstation Cleaning Procedures for Within the LeMaitre Production Facility.\u003C\u002Fp>\u003Cp>d. The records for the Equipment ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitizations performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not include written documentation that no residual sanitant remains in the system as required by MP 059, Preventive Maintenance for the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water System, which states in Section 6.4.5 (Section 5.5.5 of Exhibit F), that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized for system sterilization will provide written assurance that there is no sanitizer solution left in the system prior to releasing the system for use. WI-MFG-040, Operation of the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system Equipment ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and section 6.8.12.1 states the \u003Cstrong>(b)(4)\u003C\u002Fstrong> will provide written documentation stating that there is no residual sanitant in the system, post sanitation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your response, you provided data collected from an additional water sampling that is aligned with \u003Cstrong>(b)(4) \u003C\u002Fstrong>manufacturing that showed the water system conformed to USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water specifications, revised SOP 103 to remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> actions not reflective of \u003Cstrong>(b)(4)\u003C\u002Fstrong> use of the water system, WI MFR-40 to specify cleaning of the POU\u002FSV\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong>-POU should occur \u003Cstrong>(b)(4)\u003C\u002Fstrong> system sampling, and FRM 103-03 to allow for documentation of each required activity during water sampling. Your response also promises to revise SOP 001, PS 01, and FRM PS 01. Additionally, you provided updated MP-059 and FRM MP-006 documents that replaces \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> as well plans to update SOP 053 to require supplier change notifications to be sent to a new email address. However, your response did not provide an assessment of the new sanitant on the biocompatibility of the product or any other differences in ingredients (e.g., potential contaminants) and how your firm plans to monitor residual sanitant levels. Please provide this information and additional promised revised documents in your response to this letter.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to adequately control environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, your environmental monitoring procedure, SOP 101, does not allow for environmental samples to be collected in a manner that is reflective of the production (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) environment. For example:\u003C\u002Fp>\u003Cp>a. Section 6.5.2.3 of SOP 101 related to surface sampling states that \u003Cem>each designated workstation surface shall be cleaned per the \u003Cstrong>(b)(4)\u003C\u002Fstrong> method as described in SOP 102 prior to sample collection\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>b. Section 6.10.2 of SOP 101 related to swab sampling states that \u003Cem>each designated surface shall be cleaned per the \u003Cstrong>(b)(4)\u003C\u002Fstrong> method as described in SOP 102 prior to sample collection\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>c. Section 6.6.3 of SOP 101 related to viable air sampling states that t\u003Cem>he personnel traffic around the air sampler should be kept to a minimum so as not to artificially affect the data\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>d. Section 6.7 of SOP 101 related to non-viable air sampling does not specify when samples are to be taken (\u003Cstrong>(b)(4)\u003C\u002Fstrong> conditions).\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. In your response you provided test results from preliminary sampling collected during normal production which exhibited nominal results and were within specification along with a revised SOP 101 that now requires sampling during \u003Cstrong>(b)(4)\u003C\u002Fstrong> production for all test locations and the removal of any requirement for cleaning \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling. Your response also promises to create a form to document all sampling during \u003Cstrong>(b)(4)\u003C\u002Fstrong> production, updates to SOP 001, and performance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling during \u003Cstrong>(b)(4)\u003C\u002Fstrong> production following the revised SOP 101. In your response, please provide an update on the status of these corrective actions.\u003C\u002Fp>\u003Cp>3. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR § 820.75(a). Specifically, your firm failed to adequately validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process for the Artegraft Collagen Vascular Graft in accordance with recognized standards. According to your Sterilization Validation and Requalification document (WI-QA-012), your firm based the process sterilization validation on the requirements found in \u003Cstrong>(b)(4)\u003C\u002Fstrong> - \u003Cstrong>(b)(4)\u003C\u002Fstrong> - \u003Cstrong>(b)(4)\u003C\u002Fstrong> for validating the sterilization process used to sterilize your Artegraft devices. During review of the most recent 2023 performance qualification of the Artegraft Collagen Vascular Graft: \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process validation (VAL-PO2023) protocol and report it was noted that your firm failed to consider the bioburden of raw materials and\u002For components and their subsequent storage, and the control of the environment in which the product is manufactured, assembled, and packaged as required by \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cem>Part 1: Application of Risk Management\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. In your response you conducted a risk assessment and began testing raw materials and components. Additionally, you plan to create a procedure for sampling, testing, and analyzing raw materials and sterile barrier bioburden, as well as performing an assessment to inform testing of future raw materials and components based on results and risk. In your response, please provide an update on the status of these corrective actions.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). Specifically, your firm has not provided a documented rationale establishing the following:\u003C\u002Fp>\u003Cp>a. Section 6.1 of SOP 100, Routine Product Bioburden Testing, states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>Product Bioburden testing will be performed on a calendar\u003C\u002Fem> \u003Cem>\u003Cstrong>(b)(4) \u003C\u002Fstrong>bases, at a minimum\u003C\u002Fem>. Your firm lacks documentation for how a \u003Cstrong>(b)(4) \u003C\u002Fstrong>frequency for bioburden testing was determined to be adequate to monitor and control the Artegraft grafts. In response to the previous FDA inspection, your firm initiated CAPA 00065. As part of this CAPA, you wrote a memo justifying the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden sampling frequency stating that the \u003Cem>current frequency follows the guidance in Annex A, Section A8.1of BS EN ISO 11737-1 :2018\u003C\u002Fem>. However, six non-conformances for out of specification product bioburden samples were collected between September 2024 and March 2025 from the following lot numbers: \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There is no documented evaluation to determine if the testing frequency should be updated when out of specification bioburden test results are received. Your firm took no action based on these out of specification results justifying that decision as the organisms identified in the test were not as challenging as the sterilization challenge organism and repeat testing on a different lot of product did not result in out of specification product bioburden. Additionally, it is unclear if the sterilization process is capable of \u003Cstrong>(b)(4) \u003C\u002Fstrong>sterilization for bioburden levels as high as the challenge organism used during validation.\u003C\u002Fp>\u003Cp>b. Section 3.2 of SOP 100 defines Bioburden as: \u003Cem>The quantity of viable microorganisms on or in product and\u002For sterile barrier system\u003C\u002Fem>. However, your firm does not perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden sampling of raw material and\u002For the sterile barrier components to assess their bioburden. The only documented testing of the sterile barrier was performed during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> assessment of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> primary packaging, performed in August 2006. Additional testing of the primary packaging has not been conducted.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. In your response you provided an updated justification of bioburden testing frequency, updates made to SOP 100 that clarify the scope of pre-sterile arteries \u003Cstrong>(b)(4)\u003C\u002Fstrong>, plans to create a procedure for sampling, testing, and analyzing raw materials and sterile barrier bioburden, as well as performing an assessment to inform testing of future raw materials and components based on results and risk. In your response, please provide an update on the status of these corrective actions. Additionally, please clarify whether there were any updates considered for Section 6.10.3 of SOP 100 to include the need for increased bioburden monitoring frequency if any action level is exceeded.\u003C\u002Fp>\u003Cp>5. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 820.100(a)(4). Your firm utilizes SOP 053, Supplier Management, for supplier monitoring and issuance of supplier corrective action reports (SCARs) if necessary. Section 6.6.6 of SOP 053 states \u003Cem>If Corrective and\u002For preventive actions are deemed necessary CAPA may be initiated per SOP 050\u003C\u002Fem>. Section 6.5.6 of SOP 050 lists the requirements to perform CAPA effectiveness verification. In review of the following three closed\u002Fcompleted supplier corrective action reports (SCARs) verification of effectiveness was not documented.\u003C\u002Fp>\u003Cp>a. 2023-02 – issued on May 26, 2023, for an identified trend of failing sterility test results from a testing \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>b. 2023-03 – issued on June 20, 2023, for concerns of growth on sterility samples, including growth on the negative control, from a testing \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. 2023-004 – Concerns nonconformances\u002Fobservations identified during a \u003Cstrong>(b)(4) \u003C\u002Fstrong>audit for a sterility and bioburden testing \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your response you provided updated versions of SOP 053 (which now includes all criteria related to corrective actions; including but not limited to verification of effectiveness. Your response did not include effectiveness verification for previously closed\u002Fcompleted SCARs. Additionally, regarding SCAR 2023-02, please clarify the final disposition of grafts from lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and provide additional justification for repeating the sterility test given that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigation concluded (documented in a memo dated August 10, 2023) that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Per USP &lt;71&gt; \u003Cem>Sterility Tests\u003C\u002Fem>, a sterility test can be determined to be invalid only if it can be clearly demonstrated that the test was invalid for causes unrelated to the product to be examined. In your response, please provide the above information.\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your Corrective and Preventive Action (CAPA) procedure (SOP 050) is not being implemented in that section 6.5.3.1 of SOP 050 lists deadlines according to the identified risk of each CAPA according to Table 2 of SOP 050. There are three risk levels each with a deadline from starting an investigation to implementing a corrective or preventive action: High Risk – \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Medium Risk – \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Low Risk – \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The following are examples of CAPAs that did not meet your firm’s timeframes:\u003C\u002Fp>\u003Cp>a. High Risk CAPA\u003Cbr>i. CAPA-00068, concerns inadvertent release of nonconforming product. A total of 81 days elapsed from investigation to implementation.\u003C\u002Fp>\u003Cp>b. Medium Risk CAPAs\u003Cbr>i. CAPA-00075, environmental monitoring \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab samples that were out of specification. A total of 216 days elapsed from investigation to implementation.\u003Cbr>ii. CAPA-00078, concerns out of specification bioburden results. A total of 120 days elapsed from investigation to implementation.\u003C\u002Fp>\u003Cp>c. Low Risk CAPAs\u003Cbr>i. CAPA-00072, concerns a trend of nonconformances related to differential pressure. A total of 121 days from investigation to implementation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. In your response you provided an updated version of SOP 050 to include time for formal review and revisions if necessary and promise to review current open CAPAs and write formal extension plans, if necessary. In your response, please provide any extension plans created and an example of a CAPA that required additional investigation\u002Fplanning time, including the justification for the additional time.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Artegraft Collagen Vascular Graft devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10\u003C\u002Fp>\u003Cp>For example, your firm distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> grafts from lot 23DD203 manufactured using raw material Bovine Carotid Arteries control number \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a non‐approved supplier, one of which was implanted in a patient. You recalled the devices sometime after 6\u002F23\u002F2023. Since the product was released prior to completion of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> evaluation, as required by your firm’s procedure, and without notifying the FDA of the change in the supplier of critical materials for a Class III device, this lot of material is violative. Graft devices manufactured using raw material from an unapproved supplier could have compromised sterility or mechanical integrity, which may present a risk to health such as infection, aneurysm, pseudoaneurysm, rupture, or mechanical failure at the anastomosis leading to bleeding or explantation of the failed device. Therefore, your firm’s removal of grafts in lot 23DD203 meets the definition of a medical device removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 7\u002F1\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 713502” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Ms. Cathleen I. VanDerVeer, Senior Vice President Operations, cvanderveer@lemaitre.com\u003Cbr>Mr. Monte Nelson, Director of Quality Affairs, mnelson@lemaitre.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. George LeMaitre\n\nRecipient Title\n\nChairman and CEO\n\nLeMaitre Vascular, Inc.\n\n63 Second Ave.\n\nBurlington, MA 01803\n\nUnited States\n\nglemaitre@lemaitre.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 713502\nAugust 11, 2025\nDear Mr. LeMaitre:\nDuring an inspection of your firm located in North Brunswick, NJ from March 4, 2025, through April 16, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures Artegraft Collagen Vascular Grafts. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Monte Nelson, Sr. Director, Quality Affairs - Artegraft dated May 7, 2025, and August 5, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the May 7, 2025, response below, in relation to each of the noted violations. Any additional responses will be reviewed as part of your response to this letter.\nThese violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(e). Specifically,\na. USP water sampling procedures utilized by your firm for testing of conductivity, Total Organic Carbon (TOC), endotoxin, and microbial contamination contain inconsistent and conflicting requirements that ensure water being sampled is representative of water used in production of the Artegraft Collagen Vascular Graft devices. Specifically,\ni. Water samples for monitoring are being taken through a (b)(4) and not (b)(4) from the Point of Use (POU) as required by SOP 103, Sampling of the USP (b)(4) Water Systems, section 6.5 states that (b)(4) samples be tested from points of use (POU) according to FRM 103-03.\nii. SOP 103 is not adequate since it requires the water to be purged after system sanitization for (b)(4) sampling (section 6.12.1), requires the system to be flushed for at least (b)(4) sampling (section 6.12.2), and requires the sample port to be sprayed with (b)(4) sampling (section 6.12.5). The purging, cleaning, and spraying the sample port with (b)(4) sampling are not representative of the (b)(4) use of the water system used during production.\niii. WI MFG-040, Operation of the USP (b)(4) Water system Equipment ID #(b)(4) is not adequate since it states sample valves (SVs) will be cleaned when sampling is performed in accordance with SOP 103 (section 6.8.11.2) and states that (b)(4) POUs ((b)(4)-POU) only will be cleaned when (b)(4) is necessary, and (b)(4) system sanitation has been performed (section 6.8.11.3). This cleaning and sanitation (b)(4) sampling are not representative of the (b)(4) use of the water system used during production.\nb. Your firm changed the sterilant solution used for sanitization of the USP (b)(4) Water Systems utilized in the manufacturing process. Your firm utilizes procedure MP-059, Preventive Maintenance of the USP (b)(4) Water Systems which in sections 6.4.2 and 6.4.3 specify that (b)(4) Solution is used. However, the Maintenance Log Sheet for the USP Water System Monitoring (FRM MP-06; dated 11\u002F27\u002F24) states that (b)(4) was used for system sanitization. During the inspection, your firm’s Sr. Quality Engineer stated that (b)(4) was discontinued sometime in 2024. Your firm was unable to provide any documentation during the inspection that allowed for a different sterilant solution to be used per procedure MP-059, nor that your firm has assessed the impact of the new sterilant on devices manufactured by your firm such as on the biocompatibility or if the new sterilant has different ingredients (e.g., potential contaminants).\nc. Your firm is not documenting the (b)(4) replacement of (b)(4) during water sampling (section 6.5.2) which is required per SOP 103, Sampling of the USP (b)(4) Water Systems, which states that (b)(4) is to be replaced by a member of the quality team during (b)(4) water sampling as per SOP 102 – Workstation Cleaning Procedures for Within the LeMaitre Production Facility.\nd. The records for the Equipment ID #(b)(4) sanitizations performed on (b)(4) do not include written documentation that no residual sanitant remains in the system as required by MP 059, Preventive Maintenance for the USP (b)(4) Water System, which states in Section 6.4.5 (Section 5.5.5 of Exhibit F), that the (b)(4) utilized for system sterilization will provide written assurance that there is no sanitizer solution left in the system prior to releasing the system for use. WI-MFG-040, Operation of the USP (b)(4) Water system Equipment ID #(b)(4), and section 6.8.12.1 states the (b)(4) will provide written documentation stating that there is no residual sanitant in the system, post sanitation.\nWe reviewed your firm’s response and conclude that it is not adequate. In your response, you provided data collected from an additional water sampling that is aligned with (b)(4) manufacturing that showed the water system conformed to USP (b)(4) Water specifications, revised SOP 103 to remove (b)(4) actions not reflective of (b)(4) use of the water system, WI MFR-40 to specify cleaning of the POU\u002FSV\u002F(b)(4)-POU should occur (b)(4) system sampling, and FRM 103-03 to allow for documentation of each required activity during water sampling. Your response also promises to revise SOP 001, PS 01, and FRM PS 01. Additionally, you provided updated MP-059 and FRM MP-006 documents that replaces (b)(4) with (b)(4) as well plans to update SOP 053 to require supplier change notifications to be sent to a new email address. However, your response did not provide an assessment of the new sanitant on the biocompatibility of the product or any other differences in ingredients (e.g., potential contaminants) and how your firm plans to monitor residual sanitant levels. Please provide this information and additional promised revised documents in your response to this letter.\n2. Failure to establish and maintain procedures to adequately control environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, your environmental monitoring procedure, SOP 101, does not allow for environmental samples to be collected in a manner that is reflective of the production ((b)(4)) environment. For example:\na. Section 6.5.2.3 of SOP 101 related to surface sampling states that each designated workstation surface shall be cleaned per the (b)(4) method as described in SOP 102 prior to sample collection.\nb. Section 6.10.2 of SOP 101 related to swab sampling states that each designated surface shall be cleaned per the (b)(4) method as described in SOP 102 prior to sample collection.\nc. Section 6.6.3 of SOP 101 related to viable air sampling states that the personnel traffic around the air sampler should be kept to a minimum so as not to artificially affect the data.\nd. Section 6.7 of SOP 101 related to non-viable air sampling does not specify when samples are to be taken ((b)(4) conditions).\nThe adequacy of your firm’s response cannot be determined at this time. In your response you provided test results from preliminary sampling collected during normal production which exhibited nominal results and were within specification along with a revised SOP 101 that now requires sampling during (b)(4) production for all test locations and the removal of any requirement for cleaning (b)(4) sampling. Your response also promises to create a form to document all sampling during (b)(4) production, updates to SOP 001, and performance of (b)(4) sampling during (b)(4) production following the revised SOP 101. In your response, please provide an update on the status of these corrective actions.\n3. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR § 820.75(a). Specifically, your firm failed to adequately validate the (b)(4) sterilization process for the Artegraft Collagen Vascular Graft in accordance with recognized standards. According to your Sterilization Validation and Requalification document (WI-QA-012), your firm based the process sterilization validation on the requirements found in (b)(4) - (b)(4) - (b)(4) for validating the sterilization process used to sterilize your Artegraft devices. During review of the most recent 2023 performance qualification of the Artegraft Collagen Vascular Graft: (b)(4) sterilization process validation (VAL-PO2023) protocol and report it was noted that your firm failed to consider the bioburden of raw materials and\u002For components and their subsequent storage, and the control of the environment in which the product is manufactured, assembled, and packaged as required by (b)(4) and (b)(4), (b)(4) – Part 1: Application of Risk Management.\nThe adequacy of your firm’s response cannot be determined at this time. In your response you conducted a risk assessment and began testing raw materials and components. Additionally, you plan to create a procedure for sampling, testing, and analyzing raw materials and sterile barrier bioburden, as well as performing an assessment to inform testing of future raw materials and components based on results and risk. In your response, please provide an update on the status of these corrective actions.\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). Specifically, your firm has not provided a documented rationale establishing the following:\na. Section 6.1 of SOP 100, Routine Product Bioburden Testing, states that (b)(4) Product Bioburden testing will be performed on a calendar (b)(4) bases, at a minimum. Your firm lacks documentation for how a (b)(4) frequency for bioburden testing was determined to be adequate to monitor and control the Artegraft grafts. In response to the previous FDA inspection, your firm initiated CAPA 00065. As part of this CAPA, you wrote a memo justifying the (b)(4) bioburden sampling frequency stating that the current frequency follows the guidance in Annex A, Section A8.1of BS EN ISO 11737-1 :2018. However, six non-conformances for out of specification product bioburden samples were collected between September 2024 and March 2025 from the following lot numbers: (b)(4). There is no documented evaluation to determine if the testing frequency should be updated when out of specification bioburden test results are received. Your firm took no action based on these out of specification results justifying that decision as the organisms identified in the test were not as challenging as the sterilization challenge organism and repeat testing on a different lot of product did not result in out of specification product bioburden. Additionally, it is unclear if the sterilization process is capable of (b)(4) sterilization for bioburden levels as high as the challenge organism used during validation.\nb. Section 3.2 of SOP 100 defines Bioburden as: The quantity of viable microorganisms on or in product and\u002For sterile barrier system. However, your firm does not perform (b)(4) bioburden sampling of raw material and\u002For the sterile barrier components to assess their bioburden. The only documented testing of the sterile barrier was performed during the (b)(4) assessment of the (b)(4) primary packaging, performed in August 2006. Additional testing of the primary packaging has not been conducted.\nThe adequacy of your firm’s response cannot be determined at this time. In your response you provided an updated justification of bioburden testing frequency, updates made to SOP 100 that clarify the scope of pre-sterile arteries (b)(4), plans to create a procedure for sampling, testing, and analyzing raw materials and sterile barrier bioburden, as well as performing an assessment to inform testing of future raw materials and components based on results and risk. In your response, please provide an update on the status of these corrective actions. Additionally, please clarify whether there were any updates considered for Section 6.10.3 of SOP 100 to include the need for increased bioburden monitoring frequency if any action level is exceeded.\n5. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 820.100(a)(4). Your firm utilizes SOP 053, Supplier Management, for supplier monitoring and issuance of supplier corrective action reports (SCARs) if necessary. Section 6.6.6 of SOP 053 states If Corrective and\u002For preventive actions are deemed necessary CAPA may be initiated per SOP 050. Section 6.5.6 of SOP 050 lists the requirements to perform CAPA effectiveness verification. In review of the following three closed\u002Fcompleted supplier corrective action reports (SCARs) verification of effectiveness was not documented.\na. 2023-02 – issued on May 26, 2023, for an identified trend of failing sterility test results from a testing (b)(4)\nb. 2023-03 – issued on June 20, 2023, for concerns of growth on sterility samples, including growth on the negative control, from a testing (b)(4).\nc. 2023-004 – Concerns nonconformances\u002Fobservations identified during a (b)(4) audit for a sterility and bioburden testing (b)(4)\nWe reviewed your firm’s response and conclude that it is not adequate. In your response you provided updated versions of SOP 053 (which now includes all criteria related to corrective actions; including but not limited to verification of effectiveness. Your response did not include effectiveness verification for previously closed\u002Fcompleted SCARs. Additionally, regarding SCAR 2023-02, please clarify the final disposition of grafts from lots (b)(4), (b)(4), and (b)(4) and provide additional justification for repeating the sterility test given that the (b)(4) investigation concluded (documented in a memo dated August 10, 2023) that “(b)(4).” Per USP \u003C71> Sterility Tests, a sterility test can be determined to be invalid only if it can be clearly demonstrated that the test was invalid for causes unrelated to the product to be examined. In your response, please provide the above information.\n6. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your Corrective and Preventive Action (CAPA) procedure (SOP 050) is not being implemented in that section 6.5.3.1 of SOP 050 lists deadlines according to the identified risk of each CAPA according to Table 2 of SOP 050. There are three risk levels each with a deadline from starting an investigation to implementing a corrective or preventive action: High Risk – (b)(4); Medium Risk – (b)(4); Low Risk – (b)(4). The following are examples of CAPAs that did not meet your firm’s timeframes:\na. High Risk CAPA\ni. CAPA-00068, concerns inadvertent release of nonconforming product. A total of 81 days elapsed from investigation to implementation.\nb. Medium Risk CAPAs\ni. CAPA-00075, environmental monitoring (b)(4) swab samples that were out of specification. A total of 216 days elapsed from investigation to implementation.\nii. CAPA-00078, concerns out of specification bioburden results. A total of 120 days elapsed from investigation to implementation.\nc. Low Risk CAPAs\ni. CAPA-00072, concerns a trend of nonconformances related to differential pressure. A total of 121 days from investigation to implementation.\nThe adequacy of your firm’s response cannot be determined at this time. In your response you provided an updated version of SOP 050 to include time for formal review and revisions if necessary and promise to review current open CAPAs and write formal extension plans, if necessary. In your response, please provide any extension plans created and an example of a CAPA that required additional investigation\u002Fplanning time, including the justification for the additional time.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Artegraft Collagen Vascular Graft devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10\nFor example, your firm distributed (b)(4) grafts from lot 23DD203 manufactured using raw material Bovine Carotid Arteries control number (b)(4) from a non‐approved supplier, one of which was implanted in a patient. You recalled the devices sometime after 6\u002F23\u002F2023. Since the product was released prior to completion of the (b)(4) evaluation, as required by your firm’s procedure, and without notifying the FDA of the change in the supplier of critical materials for a Class III device, this lot of material is violative. Graft devices manufactured using raw material from an unapproved supplier could have compromised sterility or mechanical integrity, which may present a risk to health such as infection, aneurysm, pseudoaneurysm, rupture, or mechanical failure at the anastomosis leading to bleeding or explantation of the failed device. Therefore, your firm’s removal of grafts in lot 23DD203 meets the definition of a medical device removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 7\u002F1\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 713502” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Ms. Cathleen I. VanDerVeer, Senior Vice President Operations, cvanderveer@lemaitre.com\nMr. Monte Nelson, Director of Quality Affairs, mnelson@lemaitre.com","LeMaitre Vascular, Inc.","lemaitre-vascular-inc-713502-08112025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flemaitre-vascular-inc-713502-08112025","2026-10-26T08:09:13.557964+00:00","Warning Letter","Issued","2025-08-26","713502","Medical Devices","Mr. George LeMaitre","2026-08-19T16:28:55.866+00:00","VIA Electronic Mail","2025-08-11",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},190,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-15T04:00:00Z\">04\u002F15\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funetixs-vascular-inc-724245-04152026\">Unetixs Vascular, Inc.\u003C\u002Fa>","Premarket Approval\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Neeraj Jha\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unetixs Vascular, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6901 TPC Drive, Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32822\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 724245\u003C\u002Fp>\u003Cp>April 15, 2026\u003C\u002Fp>\u003Cp>Dear Neeraj Jha:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Unetixs Vascular, Inc., located in Warwick, RI from September 19, 2025, through December 4, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures vascular diagnostic ultrasound systems, including the ROODRA and 2CP devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the MultiLab Series ROODRA and 2CP vascular diagnostic devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device with its current modifications into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Specifically, the modified MultiLab Series ROODRA and 2CP vascular diagnostic devices that you are distributing do not have 510(k) clearance. While MultiLab Series ROODRA and 2CP vascular diagnostic devices have a prior 510(k) clearance (K904392), the modified devices include both design and labeling modifications – as documented in your firm’s “Regulatory Change Assessment - ENGINEERING CHANGE RECORD ECR # 0137 - Changing all applicable items from luer connections to bayonet connections” – which could significantly affect the safety and effectiveness of the device and, under 21 CFR 807.81(a)(3)(i), require a new 510(k) submission. Our review found that the change was implemented to significantly mitigate a known risk in response to an adverse event. Specifically, the device design, construction materials and labeling changes, to physically prevent device misconnections, were implemented to address a complaint of a death caused by air embolism.\u003C\u002Fp>\u003Cp>We also remind you on February 4, 2020, a Warning Letter, CMS Case #598016, was issued to you for significant quality system violations related to your vascular diagnostic ultrasound systems. We understand that while you have made progress in implementing corrective actions, deficiencies remain as documented during the recent inspection. You should continue to ensure that you are making further progress to be in compliance with all of our regulations. On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on September 19, 2025, through December 4, 2025, was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: Quality Management System Regulation – Frequently Asked Questions. The 2020 Warning Letter will remain open until we verify that you have successfully implemented all necessary corrections.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 724245” when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Vinod Ramani, Chairman, Opto Circuits (India) Ltd. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>John Haefele, Vice President, and General Manager, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>Denise Stone, Deputy General Manager, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Neeraj Jha\n\nRecipient Title\n\nPresident\u002FCEO\n\nUnetixs Vascular, Inc.\n\n6901 TPC Drive, Suite 300\n\nOrlando, FL 32822\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 724245\nApril 15, 2026\nDear Neeraj Jha:\nDuring an inspection of your firm, Unetixs Vascular, Inc., located in Warwick, RI from September 19, 2025, through December 4, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures vascular diagnostic ultrasound systems, including the ROODRA and 2CP devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the MultiLab Series ROODRA and 2CP vascular diagnostic devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device with its current modifications into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSpecifically, the modified MultiLab Series ROODRA and 2CP vascular diagnostic devices that you are distributing do not have 510(k) clearance. While MultiLab Series ROODRA and 2CP vascular diagnostic devices have a prior 510(k) clearance (K904392), the modified devices include both design and labeling modifications – as documented in your firm’s “Regulatory Change Assessment - ENGINEERING CHANGE RECORD ECR # 0137 - Changing all applicable items from luer connections to bayonet connections” – which could significantly affect the safety and effectiveness of the device and, under 21 CFR 807.81(a)(3)(i), require a new 510(k) submission. Our review found that the change was implemented to significantly mitigate a known risk in response to an adverse event. Specifically, the device design, construction materials and labeling changes, to physically prevent device misconnections, were implemented to address a complaint of a death caused by air embolism.\nWe also remind you on February 4, 2020, a Warning Letter, CMS Case #598016, was issued to you for significant quality system violations related to your vascular diagnostic ultrasound systems. We understand that while you have made progress in implementing corrective actions, deficiencies remain as documented during the recent inspection. You should continue to ensure that you are making further progress to be in compliance with all of our regulations. On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on September 19, 2025, through December 4, 2025, was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: Quality Management System Regulation – Frequently Asked Questions. The 2020 Warning Letter will remain open until we verify that you have successfully implemented all necessary corrections.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 724245” when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon at karen.archdeacon@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc:\nVinod Ramani, Chairman, Opto Circuits (India) Ltd. (b)(4)\nJohn Haefele, Vice President, and General Manager, (b)(4)\nDenise Stone, Deputy General Manager, (b)(4)","Unetixs Vascular, Inc.","unetixs-vascular-inc-724245-04152026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funetixs-vascular-inc-724245-04152026","2026-10-26T08:10:17.395391+00:00","2026-05-05","724245","Mr. Neeraj Jha","2026-08-19T04:45:17.638+00:00","2026-04-15",{"id":51,"raw":52,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":42,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":19,"body_fetched_at":68,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":70,"medical_device_id":19,"response_letter_date":19},110,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnova-vascular-llc-dba-novarx-728290-06082026\">Nova Vascular LLC dba NOVARX\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Nova Vascular LLC dba NOVARX\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>99 Wall Street, #878\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10005\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@novarx.com\"> info@novarx.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728290\u003C\u002Fp>\u003Cp>To NOVARX:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of NOVARX’s website, https:\u002F\u002Fnovarx.co, FDA Establishment Identifier (FEI) 3044022416, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The compounded semaglutide and tirzepatide products displayed on your website identify “NOVA RX” on the pictured label, suggesting NOVARX is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“…access to the same active ingredient found in Ozempic.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>3. Your website claims that the compounded drug products it offers are sourced from “FDA Approved Pharmacies.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&amp;C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728290 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&amp;C Act § 503(b) [21 U.S.C. § 353(b)], FD&amp;C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&amp;C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products. Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nNova Vascular LLC dba NOVARX\n\n99 Wall Street, #878\n\nNew York, NY 10005\n\nUnited States\n\ninfo@novarx.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728290\nTo NOVARX:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of NOVARX’s website, https:\u002F\u002Fnovarx.co, FDA Establishment Identifier (FEI) 3044022416, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The compounded semaglutide and tirzepatide products displayed on your website identify “NOVA RX” on the pictured label, suggesting NOVARX is the compounder of those drugs when in fact it is not.2\n2. The following claims concerning compounded semaglutide products appear on your website:\n“…access to the same active ingredient found in Ozempic.”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\n3. Your website claims that the compounded drug products it offers are sourced from “FDA Approved Pharmacies.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities.3 Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728290 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&C Act § 503(b) [21 U.S.C. § 353(b)], FD&C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\n3 While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products. Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs).","Nova Vascular LLC dba NOVARX","nova-vascular-llc-dba-novarx-728290-06082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnova-vascular-llc-dba-novarx-728290-06082026","2026-10-26T08:09:35.154319+00:00","2026-06-16","728290","Drugs","2026-08-19T04:36:13.259+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",3,{"510k":73,"classification":74,"enforcement":75,"event":76,"event_backfill":77,"pma":78,"warning_letter":79},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]